Results 101 to 110 of about 51,483 (212)

Postnatal and non-invasive prenatal detection of β-thalassemia mutations based on Taqman genotyping assays [PDF]

, 2017
The β-thalassemias are genetic disorder caused by more than 200 mutations in the β-globin gene, resulting in a total (β0) or partial (β+) deficit of the globin chain synthesis. The most frequent Mediterranean mutations for β-thalassemia are: β039, β+ VSI-
Borgatti, Monica, Breveglieri, Giulia, Cosenza, Lucia Carmela, D'Aversa, Elisabetta, Gambari, Roberto, Guerra, Giovanni, Pellegatti, Patrizia, Travan, Anna   +7 more
core   +2 more sources

Improved Outcomes for Older Children, Adolescents, and Young Adults With Neuroblastoma in the Post‐Immunotherapy Era: An Updated Report From the International Neuroblastoma Risk Group

Pediatric Blood &Cancer, Volume 73, Issue 4, April 2026.
ABSTRACT Background We describe clinical and biologic characteristics of neuroblastoma in older children, adolescents, and young adults (OCAYA); describe survival outcomes in the post‐immunotherapy era; and identify if there is an age cut‐off that best discriminates outcomes.
Rebecca J. Deyell, Kavitha Srivatsa, Paola Angelini, Pei‐Chi Kao, Brady Payne, Arlene Naranjo, Sveva Castelli, Miho Kato, Miki Ohira, Ulriche Pöetschger, Yaël Mossé, Lucas Moreno, Meredith S. Irwin, Ramya Ramanujachar, Wendy B. London   +14 more
wiley   +1 more source

Effect of Red Blood Cell Transfusion on Inflammatory and Angiogenic Pathways in Patients With Sickle Cell Disease

American Journal of Hematology, Volume 101, Issue 4, Page 718-727, April 2026.
ABSTRACT Sickle cell disease (SCD) is a chronic inflammatory state, characterized by increased plasma values of inflammatory and angiogenic proteins. Although red blood cell (RBC) transfusion is known to have immunomodulatory effects in other conditions, its potential effects on the inflammatory state in SCD remain largely unknown.
Lydian A. de Ligt, Sanjay R. Thakoerdin, Maud Zwolsman, Gaby Stegemann, Hanke Matlung, Taco W. Kuijpers, Bart J. Biemond, Karin Fijnvandraat, Robin van Bruggen, Erfan Nur   +9 more
wiley   +1 more source

Hematological ratios and cytokine profiles in heterozygous beta-thalassemia

Hematology, Transfusion and Cell Therapy
Introduction: β-Thalassemia is defined by a reduced or complete absence of β-globin chain synthesis in hemoglobin, leading to hemolytic anemia. Heterozygous β-thalassemia, also known as β-thalassemia trait (hBTh), the mildest form of this anemia ...
Ana Carolina Marques Ciceri, Laura Eduarda de Oliveira, Ana Luísa Richter, José Antonio Mainardi de Carvalho, Maylla Rodrigues Lucena, Guilherme Wataru Gomes, Maria Stella Figueiredo, Magnun Nueldo Nunes dos Santos, Vera Lúcia Nascimento Blaia-D'Avila, Rodolfo Delfini Cançado, Elvira Maria Guerra-Shinohara, Clóvis Paniz   +11 more
doaj   +1 more source

The correlation between HLA class II and β-thalassemia major in Al-Karama teaching hospital

مجلة كلية الطب, 2016
Background: Thalassemia is a form of inherited autosomal recessive blood disorder characterized by abnormal formation of hemoglobin. Objective: Determine frequencies & association of HLA class II alleles (DRB1& DQB1) in Iraqi β-thalassemia major patients.
Sarmad M. Zeiny
doaj   +1 more source

Insulin-like growth factor-1 levels in children with Beta-thalassemia minor [PDF]

, 2008
Objective: Growth retardation in children with b-thalassemia major is multifactorial. Some etiologies described for this condition are hemochromatosis, disturbed growth hormone (GH) / insulin growth factor-1 (IGF-1) axis, undernutrition and ...
Hamdollah Karamifar, Mehran Karimi, Nargrs Sobhani   +2 more
core  

Continuum of care after newborn screening for sickle cell disease: Multinational evidence from a systematic review and meta‐analysis

British Journal of Haematology, EarlyView.
Tanveer Rehman, Srijeeta Mitra, Kalpita Ganpat Gawit, Ravindra Kumar, Sritama Dutta, Ananya Anurakta Pattanaik, Lakhan Majhee, Tanu Anand, Manisha Madkaikar, Sanghamitra Pati   +9 more
wiley   +1 more source

Creative and Adaptive Solutions for Early Diagnosis of Sickle Cell Disease in Sub‐Saharan Africa

American Journal of Hematology, Volume 101, Issue S1, Page 17-32, April 2026.
ABSTRACT Many of the children with sickle cell disease born in sub‐Saharan Africa remain undiagnosed and untreated. Increasing capacity and infrastructure to support diagnostic and screening programs in high income countries have enabled near universal survival into adulthood.
Luke R. Smart, Catherine I. Segbefia, Isaac Odame   +2 more
wiley   +1 more source

Real‐world evidence supports the safety and efficacy profile of luspatercept in clinically complex and heavily iron‐overloaded patients

British Journal of Haematology, EarlyView.
Barbara Gianesin, Antonietta Zappu, Giovanni Battista Ferrero, Carmen Maria Gaglioti, Michele Santodirocco, Giuseppe Fania, Giovanna Graziadei, Daniele Lello Panzieri, Antonella Massa, Tommaso Mina, Francesca Polese, Angelantonio Vitucci, Francesco Arcioni, Maria Caterina Putti, Valerio Cecinati, Ilaria Fotzi, Paola Maria Grazia Sanna, Antonio Cappello, Filomena Longo, Roberto Lisi, Annamaria Pasanisi, Daniela Pietrasanta, Monica Bocchia, Elisa Bertoni, Antonella Cossu, Marilena Serra, Susanna Barella, Antonia Gigante, Gian Luca Forni, Raffaella Origa   +29 more
wiley   +1 more source

The Epidemiology of Sickle Cell Disease in Sub‐Saharan Africa: Current Knowledge and Gaps to be Filled

American Journal of Hematology, Volume 101, Issue S1, Page 5-16, April 2026.
What are the available data on incidence & prevalence prognosis risk factors of severity of sickle cell disease in sub‐Saharan Africa? ABSTRACT Sickle Cell Disease (SCD) is highly prevalent in sub‐Saharan Africa. Epidemiological data remain sparse, but regional screening and research initiatives are expanding.
Brigitte Ranque, Leon Tshilolo, Thomas N. Williams   +2 more
wiley   +1 more source